---
title: "TJPC's subsidiary has obtained the drug registration certificate for Butorphanol Tartrate Injection"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263684157.md"
description: "TJPC's subsidiary Tianjin Jiayuan Peace Pharmaceutical Co., Ltd. recently obtained the drug registration certificate for Butorphanol Tartrate Injection issued by the National Medical Products Administration. This drug is mainly used for the treatment of cancer pain and postoperative pain, and it falls under the category of second-class psychotropic drugs. Jiayuan Peace submitted the registration application in October 2023 and received the certificate in October 2025, with a total R&D investment of approximately 22 million yuan"
datetime: "2025-10-31T08:08:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263684157.md)
  - [en](https://longbridge.com/en/news/263684157.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263684157.md)
---

# TJPC's subsidiary has obtained the drug registration certificate for Butorphanol Tartrate Injection

According to the Zhitong Finance APP, TJPC (600488.SH) announced that its subsidiary Tianjin Pharmaceutical Co., Ltd. (referred to as "TJPC") has received the "Drug Registration Certificate" for Buprenorphine Tartrate Injection issued by the National Medical Products Administration.

The main ingredient of Buprenorphine Tartrate Injection is Buprenorphine Tartrate, which is classified as a Class II controlled substance under the national "Regulations on the Administration of Narcotic Drugs and Psychotropic Substances." Its indications include the treatment of various cancer-related pain and postoperative pain. In October 2023, TJPC submitted an application for the domestic production drug registration and marketing license of this drug to the Drug Evaluation Center of the National Medical Products Administration, which was accepted, and it obtained the drug registration certificate issued by the National Medical Products Administration in October 2025. So far, TJPC has invested approximately 22 million yuan in research and development costs for the Buprenorphine Tartrate Injection project

### Related Stocks

- [600488.CN](https://longbridge.com/en/quote/600488.CN.md)

## Related News & Research

- [UTG Chairman and CEO Jesse T. Correll buys 4,850 shares for $266,556.00](https://longbridge.com/en/news/287109106.md)
- [HSA warns public against consuming herbal remedy containing potent steroid](https://longbridge.com/en/news/287022845.md)
- [China and Russia to boost cooperation in oil, gas, and coal.](https://longbridge.com/en/news/287088733.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [FDA drug center head fired after commissioner's exit](https://longbridge.com/en/news/286647070.md)